|Bid||42.05 x 1100|
|Ask||44.25 x 800|
|Day's Range||43.06 - 44.23|
|52 Week Range||40.00 - 45.62|
|Beta (3Y Monthly)||0.40|
|PE Ratio (TTM)||22.53|
|Forward Dividend & Yield||1.74 (3.97%)|
|1y Target Est||N/A|
A commonly used heartburn medicine from Sanofi, known as Zantac, could contain cancer-causing substances, the Food and Drug Administration said Friday. Sanofi stock fell a fraction.
Investing.com - U.S. and European health officials are investigating big-selling heartburn treatment Zantac and generics of the drug after a carcinogen was discovered in low levels, Bloomberg first reported Friday.
J&J (JNJ) announces superiority of its multiple sclerosis candidate, ponesimod compared to Sanofi's Aubagio in patients with relapsing form of the disease.
In addition to a $260 million payout, the drug dispute settlement returns worldwide development and commercialization rights to Houston-area firm.
The company has burned through $400 million, laid off employees and lost two Big Pharma partnerships, but now it is near an FDA drug approval for people with a debilitating bowel disorder.
Lexicon Pharmaceuticals (LXRX) settles with Sanofi related to termination of their alliance for development of Zynquista in type I and type II diabetes.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 10) Ardelyx Inc (NASDAQ: ARDX ) Avedro Inc (NASDAQ: AVDR ...
Lexicon Pharmaceuticals Inc said on Tuesday France's Sanofi SA will pay the drugmaker $260 million for the termination of their partnership to develop diabetes drug Zynquista. Under the terms of the settlement, Sanofi will pay $208 million upfront and the remainder within twelve months to Lexicon, which was eligible to receive up to $1.4 billion in milestone payments under the partnership. The four-year partnership was terminated by Sanofi in July after the results of three late-stage studies of Zynquista, which is being developed as an add-on to insulin for diabetic patients.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Novo Nordisk will offer cheaper insulin to U.S. diabetics, the Danish drugmaker said on Friday, in response to criticism over the high price of the medication and after similar moves by rivals Sanofi and Eli Lilly. President Donald Trump has made high prescription drug prices a top issue in the 2016 presidential campaign and said that drug companies were "getting away with murder". Novo will offer a generic version of its most heavily prescribed insulin drug Novolog, used by about a million U.S. patients, at a 50% discount compared to the current list price, the company said in a statement.
Novartis' (NVS) generics unit, Sandoz, inks deal with Polpharma Biologics for a proposed natalizumab biosimilar for the treatment of RRMS.
Moody's Investors Service ("Moody's") has today affirmed the Prime-1 (P-1) short-term Commercial Paper ratings of both L'Oréal S.A. and its US subsidiary L'Oréal U.S.A. Inc. The outlook is stable. The affirmation of L'Oréal's Prime-1 (P-1) short-term Commercial Paper rating reflects the group's strong business profile, solid profitability and very strong credit metrics. Moody's expects the group's growth to continue to outperform the global beauty market.
Bernstein initiated coverage on Tuesday with an Outperform rating, saying that the company is well-positioned to succeed over the next few years.
A combination regimen of Esperion (ESPR) and Merck's Zetia significantly improves bad cholesterol (LDL-C) levels in patients with both hypercholesterolemia and type II diabetes.